Contract Award
Physiomics awarded £98,600 contract for PK/PD modelling supporting preclinical-to-clinical translation.
- Contract value £98,600
- Contract duration 18 months
Select text to share a quote on X · sign in to keep highlights & notes in your PYC notes
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract award with an existing client.
In this new project, Physiomics will apply PK/PD modelling and simulation expertise to support preclinical-to-clinical translation for one of the client's lead candidates and inform selection of human dosing schemes for a First in Human clinical trial.
This contract, which supports the development of a non-oncology therapeutic, highlights the value of Physiomics' integrated modelling and simulation approach across the drug development lifecycle - from early discovery through translational planning and into clinical development. The contract is valued at £98,600 and will be delivered over the next 18 months.
Dr Peter Sargent, CEO of Physiomics, commented:
"We are delighted to continue partnering with this client and announce this follow on work with their team. Working with them from early discovery through to clinical planning enables us to add deeper insights into their experimental and clinical trial design, helping them accelerate this promising drug development programme."
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.